Table 1.
Correlation between ZEB1-AS1 expression and clinicopathological characteristics in 100 glioma patients
| Characteristics | All (n = 100) | ZEB1-AS1 expression | ||
|---|---|---|---|---|
|
| ||||
| High expression (%) | Low expression (%) | P value | ||
| Age (year) | ||||
| < 50 | 45 | 15 (33.3) | 30 (66.7) | 0.384 |
| ≥ 50 | 55 | 23 (41.8) | 32 (58.2) | |
| Gender | ||||
| Male | 58 | 24 (41.4) | 34 (58.6) | 0.741 |
| Female | 42 | 16 (38.1) | 26 (61.9) | |
| Tumor size | ||||
| ≤ 30 mm | 65 | 26 (40.0) | 39 (60.0) | 0.006* |
| > 30 mm | 35 | 24 (68.6) | 11 (31.4) | |
| TNM stage | ||||
| I/II | 47 | 12 (25.5) | 35 (74.5) | 0.015* |
| III/IV | 53 | 26 (49.1) | 27 (50.9) | |
| Tumor location | ||||
| Frontal | 28 | 7 (25.0) | 21 (75.0) | 0.252 |
| Parietal | 10 | 3 (30.0) | 7 (70.0) | |
| Occipital | 16 | 6 (37.5) | 10 (62.5) | |
| Temporal | 20 | 7 (35.0) | 13 (65.0) | |
| Others | 26 | 12 (46.2) | 14 (53.8) | |
*
The values had statistically significant differences.